The European Hereditary Tumour Group (EHTG) is a multidisciplinary organisation committed to advancing interdisciplinary research, collaborative studies, and global networking in the field of hereditary cancer syndromes. The Society’s overarching mission is to enhance understanding and improve the diagnosis, prevention, and treatment of hereditary tumour syndromes across all relevant clinical and scientific disciplines.
The EHTG Annual Meeting reflects this mission through a distinctive structure that combines high-quality plenary sessions with interactive Working Group (WG) formats, designed to foster both learning and collaboration.
- The plenary sessions feature state-of-the-art lectures delivered by international experts, covering the latest research, guideline updates, and emerging topics in hereditary cancer. These are complemented by panel and podium discussions, allowing cross-disciplinary debate and contextualisation of new findings into clinical practice.
- The Working Group sessions provide focused platforms for deeper engagement within key specialist domains. Abstracts submitted to the meeting are independently reviewed by an external scoring committee assigned to each WG, ensuring scientific rigour and transparency. The meeting accommodates up to 50 accepted abstracts for oral and poster presentation, promoting early-career engagement and showcasing cutting-edge research.
- Beyond presentations, WG sessions also provide dedicated time and space for proposing, planning, and advancing collaborative research projects, in line with EHTG’s aim to build sustainable, multicentre networks that drive innovation in hereditary cancer care.
This blended format ensures that the EHTG meeting is not only a scientific forum but also a catalyst for practical collaboration and clinical impact.